GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Medexus Pharmaceuticals MDP.TO · CAD

Health Care · Toronto Stock Exchange · 🇨🇦 Canada

Compare

5.23

+2.15%

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Medexus Pharmaceuticals — daily TSX:MDP Delayed
Market value
C$169.6m
Last close × shares
Volume
38.1k
Shares, 9 Nov 2026
Price to earnings
51.0

About Medexus Pharmaceuticals

Its shares trade on Toronto Stock Exchange under the ticker MDP.TO. It has been listed since 3 March 2012. In the fiscal year to 31 March 2025, it reported revenue of $108.3m and net income of $2.2m. At that date it held total assets of $171.8m and shareholders' equity of $52.1m.

Medexus Pharmaceuticals, Inc. operates as a pharmaceutical company, which engages in the development and commercialization of pharmaceutical products and treatment solutions focusing on therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. The company is headquartered in Bolton, Ontario. The company went IPO on 2012-03-03. The firm has a portfolio of rare disease treatment solutions. The firm is focused on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy and dermatology. The firm has two divisions: Medexus Pharma Canada and Medexus Pharma USA. Medexus Pharma Canada division is a fully integrated commercial infrastructure focused on rheumatology, allergy, auto-immune disease, specialty oncology and pediatric diseases in Canada. The division’s prescription products include Metoject (Methotrexate Injection), Rupall (Rupatadine), Cuvposa (Glycopyrrolate Oral Solution), Pediapharm Naproxen Suspension (Naproxen) and others. Medexus Pharma USA division is a fully integrated commercial infrastructure focused on rheumatology and auto-immune diseases in the United States. The division’s products include Rasuvo, IXINITY and Gleolan.

Figures and description from our data supplier, not checked against the company's own report.

More about Medexus Pharmaceuticals →

Latest on Medexus Pharmaceuticals

Our reporting

We have not reported on Medexus Pharmaceuticals yet.

Next results

11 Nov 2026

Due on 11 Nov 2026. Analysts expect earnings of 0.03 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Medexus Pharmaceuticals's ticker?

Medexus Pharmaceuticals trades as MDP.TO on Toronto Stock Exchange, under ISIN CA58410Q2036.

What was Medexus Pharmaceuticals's last closing price?

5.23 on 9 Nov 2026. The figure is in CAD and is never converted.

When does Medexus Pharmaceuticals next report results?

Results are expected on 11 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.